Printer Friendly

VERIDIEN SHAREHOLDERS AMEND COMPANY'S BYLAWS TO PERMIT GREATER FLEXIBILITY IN APPOINTMENT OF DIRECTORS

 VERIDIEN SHAREHOLDERS AMEND COMPANY'S BYLAWS TO PERMIT
 GREATER FLEXIBILITY IN APPOINTMENT OF DIRECTORS
 TAMPA, Fla., April 13 /PRNewswire/ -- Veridien Corporation (OTC Bulletin Board: VERD), a healthcare products company headquartered in Tampa, announced that on April 1, company shareholders owning a majority of the company's outstanding voting common stock, by special written action and consent taken without a meeting, amended the company's bylaws to permit shareholders greater flexibility in the appointment of directors. The number of company directors was increased from nine to 12 and five new directors were appointed. New directors are Paul L. Simmons, D. Jerry Diamond, Gerald Pennington, John E. Scott and Marvin Weathers. The shareholder action was taken pursuant to Delaware law and in accordance with applicable provisions of the company's bylaws.
 The company's expanded board of directors held a specially called meeting on April 2 at which Simmons was elected chairman of the board of directors and interim chief executive officer. Diamond was elected interim chief operating officer, and Omar el-Abd, an incumbent company director, was elected chief financial officer. Simmons is the company's founder and currently chairman of its research and development subsidiary, Rost, Inc. Diamond was chairman, president and chief executive officer of Coastland Corporation of Florida, a publicly traded company conducting operations in the waste recycling industry, prior to joining Rost as chief operating officer. el-Abd is also the company's vice chairman and since January 1989 is the chief executive officer of Credit des Bergues, Geneva, Switzerland, an investment banking firm specializing in portfolio management and has held prior positions with The First Boston Corporation and Salomon Brothers.
 At that same April 2 director's meeting, a letter of resignation from John W. Reeder, M.D., was referred to and his resignation from the board of directors, due to time constraints and other personal reasons was accepted, reducing its number to 11 and and leaving one vacancy.
 The principal shareholder and director actions reported above resulted directly from the resignation, tendered to and accepted by the board of directors on Saturday, March 28, of Robert E. Yaw II, the company's chief executive officer and board chairman, and Wayne L. Taylor, its vice president, comptroller and treasurer. Both resignations resulted from a dispute relating to the excessiveness of compensation payable or paid to each by the company. On April 10, the board of directors agreed to approve a compensation arrangement for the period 1990 through March 1992 for Yaw, and Yaw accepted the board's action. Chairman Simmons described the agreement as one which is in the best interest of the company and its shareholders.
 In addition, chairman Simmons today announced that the company's 510(K) FDA submission for Veridien Cold Chemical Sterilant was recently expanded to include a universal "high grade" disinfectant, an efficacy monitor and programmable ultrasonic processing systems -- in sum, a proprietary decontamination and sterilizing system rather than sterilant and disinfectant devices only. He also noted that original clinical trials of the new Cold Chemical Sterilant have been successfully completed at the University of Florida under the direction of Dr. Frank W. Stout, associate professor of Oral Diagnostic Sciences and director of the Sterilization Monitoring and Consultation Service at the College of Dentistry.
 Stout, who is a member of the company's Scientific Advisory Board, has reported that his tests of Veridien Cold Chemical Sterilant and Veridien Disinfectant have met or exceeded the company's claims and both products appear to have widespread applications. "I'm surprised and impressed with the performance of both products," said Stout. "The disinfectant is effective, biodegradable and easy to use. The ten-minute Cold Chemical Sterilant fills a long-term need. This is very good news for dentists and all healthcare providers."
 The company also announced receipt of U.S. patent allowance for Viraholl, the company's core technology. Patent pending notice has also been received for Veridien Cold Chemical Sterilant and Veridien hospital-grade floor disinfectant.
 -0- 4/13/92
 /CONTACT: Paul L. Simmons or Omar el-Abd of Veridien Corporation, 813-623-1423/
 (VERD) CO: Veridien Corporation ST: Florida IN: MTC HEA SU:


JJ-SS -- FL019 -- 7889 04/13/92 15:35 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 13, 1992
Words:677
Previous Article:SEVENTEEN CIVILIANS RECEIVE AIR MEDALS FROM U.S. AIR FORCE FOR OPERATION DESERT STORM
Next Article:ALCOA ISSUES EARNINGS


Related Articles
VERIDIEN CORPORATION SEEKS INVESTMENT BANKING FIRM ASSISTANCE
/C O R R E C T I O N -- VERIDIEN/
Why pray when you can order?
Erie Indemnity Board Amends Bylaws.
SulphCo's Largest Shareholder Files Suit Against Members of the Company's Board of Directors.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters